Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel

Autor: Gert A. van Deijk, Linda de Munck, Anneke M. Westermann, Willem M. Smit, Geert-Jan Creemers, Carolien P. Schröder, Willemijn Vader, Zoran Erjavec, Pax H.B. Willemse, Aart van Bochove, Hiltje de Graaf, Jacqueline M. Stouthard

Publikováno v: European journal of cancer (Oxford, England, 47(9), 1355-1362. Elsevier Limited
European Journal of Cancer, 47(9), 1355-1362. ELSEVIER SCI LTD

Background: In anthracycline-pretreated metastatic breast cancer (MBC) patients, it is unknown whether weekly single-agent docetaxel is preferable to 3-weekly docetaxel regarding its toxicity and efficacy profile.Patients and methods: In this multice

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1a3d7c2d465aa750ac0500a456cb69b
https://doi.org/10.1016/j.ejca.2010.12.018

Refinement of the genetic cause of ATR-16

Autor: Astrid Voskamp, Cornelis L. Harteveld, Zoran Erjavec, Marjolein Kriek, Stefan J. White, Piero C. Giordano, Marion Phylipsen, Emilia K. Bijlsma, Emmanora di Capua, Deepak M.W. Balak

Publikováno v: Human genetics. 122(3-4)

Alpha thalassemia retardation associated with chromosome16 (ATR-16 syndrome) is defined as a contiguous gene syndrome resulting from haploinsufficiency of the alpha-globin gene cluster and genes involved in mental retardation (MR). To date, only few

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6d6978df19ab267310f96d6940bb4c7
https://pubmed.ncbi.nlm.nih.gov/17598130

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3) : a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Autor: Hans J Braun, Olaf Loosveld, Albert J. ten Tije, Adelheid M. E. van der Torren, Cornelis J. A. Punt, Jacobus J.M. van der Hoeven, Miriam Koopman, Aafk E. H. Honkoop, Frans L. G. Erdkamp, Jaap Wals, Rob L. H. Jansen, Anne May, Peter Nieboer, Veerle A. Derleyn, Lieke H.J. Simkens, Annemieke Cats, Felix E de Jongh, Zoran Erjavec, Linda Mol, Jolien Tol, Geert-Jan Creemers, Janny G. Haasjes, Harm van Tinteren

Publikováno v: Lancet, 385(9980), 1843-1852. Elsevier Limited
The Lancet, 385(9980), 1843. Elsevier Limited
Lancet, 385(9980), 1843-1852. Elsevier Science
The Lancet (London), 385, 9980, pp. 1843-52
The Lancet (London), 385, 1843-52

Item does not contain fulltext BACKGROUND: The optimum duration of first-line treatment with chemotherapy in combination with bevacizumab in patients with metastatic colorectal cancer is unknown. The CAIRO3 study was designed to determine the efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d341513745af9240b05212b8aba4b77
https://hdl.handle.net/1874/337788

Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG)

Autor: Jürgen Braun, Otilia Dalesio, Linda Mol, Lieke H.J. Simkens, Felix E. de Jongh, Peter Nieboer, Annemieke Cats, Jacobus J. M. van der Hoeven, Miriam Koopman, Geert-Jan Creemers, Harm van Tinteren, J. Wals, Janny G. Haasjes, Rob L. H. Jansen, Frans L. G. Erdkamp, Olaf Loosveld, Adelheid M. E. van der Torren, Cornelis J. A. Punt, Albert J. ten Tije, Zoran Erjavec

Publikováno v: Journal of Clinical Oncology. 31:3502-3502

3502 Background: The optimal duration of chemotherapy and bevacizumab in mCRC is not well established. The CAIRO3 study investigated the efficacy of maintenance treatment with capecitabine plus bevacizumab versus observation in mCRC pts not progressi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2146489b2c18c90458e18b3268f8b339
https://doi.org/10.1200/jco.2013.31.15_suppl.3502